Actinogen Medical (ASX:ACW) dosed the first participant of a phase 2b/3 trial in the US of XanaMIA in patients with biomarker-positive mild to moderate Alzheimer's disease, according to a Monday filing with the Australian bourse.
The study aims to enroll 220 participants with elevated levels of the Alzheimer's disease biomarker pTau181, the filing said. The improvement in the Clinical Dementia Rating-Sum of Boxes scale is the primary endpoint, and the Amsterdam Activity of Daily Living scale is the secondary endpoint.
Participants will receive either 10 mg of the drug candidate or placebo daily for 36 weeks, per the filing.
Company shares rose nearly 7% in recent Monday trade.
Price (AUD): $0.03, Change: $+0.002, Percent Change: +6.45%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.